Heyu Biological Technology Corporation
Heyu Biological Technology Corporation Fundamental Analysis
Heyu Biological Technology Corporation (HYBT) shows weak financial fundamentals with a PE ratio of 241.19, profit margin of 6.62%, and ROE of 1.84%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 36.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze HYBT's fundamental strength across five key dimensions:
Efficiency Score
WeakHYBT struggles to generate sufficient returns from assets.
Valuation Score
WeakHYBT trades at a premium to fair value.
Growth Score
WeakHYBT faces weak or negative growth trends.
Financial Health Score
ModerateHYBT shows balanced financial health with some risks.
Profitability Score
ModerateHYBT maintains healthy but balanced margins.
Key Financial Metrics
Is HYBT Expensive or Cheap?
P/E Ratio
HYBT trades at 241.19 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, HYBT's PEG of 2.76 indicates potential overvaluation.
Price to Book
The market values Heyu Biological Technology Corporation at 4.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 313.82 times EBITDA. This signals the market has high growth expectations.
How Well Does HYBT Make Money?
Net Profit Margin
For every $100 in sales, Heyu Biological Technology Corporation keeps $6.62 as profit after all expenses.
Operating Margin
Core operations generate 8.16 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.84 in profit for every $100 of shareholder equity.
ROA
Heyu Biological Technology Corporation generates $1.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Heyu Biological Technology Corporation generates limited operating cash flow of $-8.44M, signaling weaker underlying cash strength.
Free Cash Flow
Heyu Biological Technology Corporation generates strong free cash flow of $15.66M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.02 in free cash annually.
FCF Yield
HYBT converts 2.18% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
241.19
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
2.76
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.29
vs 25 benchmark
P/S Ratio
Price to sales ratio
31.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.19
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.85
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How HYBT Stacks Against Its Sector Peers
| Metric | HYBT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 241.19 | 29.45 | Worse (Expensive) |
| ROE | 1.84% | 779.00% | Weak |
| Net Margin | 6.62% | -24930.00% (disorted) | Weak |
| Debt/Equity | 0.19 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 0.85 | 4.65 | Weak Liquidity |
| ROA | 1.14% | -19333.00% (disorted) | Weak |
HYBT outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Heyu Biological Technology Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation